Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - The …, 2015 - academic.oup.com
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
[PDF][PDF] Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
M AAPRO, A CARIDES, BL RAPOPORT, HJ SCHMOLL… - academia.edu
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll, L Zhang… - The Oncologist, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Chemotherapy-induced nausea and vomiting
(CINV) is a common adverse event associated with anticancer treatment that can have a …
(CINV) is a common adverse event associated with anticancer treatment that can have a …
[PDF][PDF] Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
M AAPRO, A CARIDES, BL RAPOPORT, HJ SCHMOLL… - Citeseer
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
M Aapro, A Carides, BL Rapoport… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
[PDF][PDF] Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - The …, 2015 - Wiley Online Library
Chemotherapy‐induced nausea and vomiting (CINV) is a common adverse event
associated with anticancer treatment that can have a significant adverse impact on patient …
associated with anticancer treatment that can have a significant adverse impact on patient …
[HTML][HTML] Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - The …, 2015 - ncbi.nlm.nih.gov
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - The …, 2015 - europepmc.org
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety.
M Aapro, A Carides, BL Rapoport, HJ Schmoll… - …, 2015 - search.ebscohost.com
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …
[PDF][PDF] Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
M AAPRO, A CARIDES, BL RAPOPORT, HJ SCHMOLL… - researchgate.net
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …
with anticancer treatment that can have a significant adverse impact on patient health …